Maintenance of therapeutic concentrations of micafungin administered 5 days/week in a leukemic adolescent with invasive candidiasis

n/

Actividad biológica de Solanum glaucophyllum en la Provincia de Buenos Aires, Argentina

Solanum glaucophyllum (SG) es una potente planta calcinogénica que en Argentina ocasiona la enfermedad conocida como enteque seco (ES) del ganado de cría. Su principio activo es el glicósido del metabolito activo de la vitamina D3. Para conocer las posibles variaciones espaciales y temporales de la potencia biológica de SG, se evaluó la actividad vitamina D (AVD) de la planta, determinando la concentración de 1,25(OH)2vitamina D3 por HPLC luego de hidrólisis enzimática, en hojas recogidas en diferentes emplazamientos de distintas localidades de la Provincia de Buenos Aires, entre noviembre de 2003 y junio de 2004. Se relacionó AVD del vegetal con el paisaje del emplazamiento. También se consignaron la pastura acompañante y el estado fenológico preponderante del SG en los emplazamientos. Los valores de AVD, que estuvieron dentro del rango 8,6 a 39,6 μg/g, disminuyeron de noviembre a junio (b= –0,1425; p= 0,0316) en emplazamientos fijos seleccionados. Con esta ecuación se calculó la AVD al día 98 del período de recolección (AVDCORR) para los 36 valores del mapeo. Se observó variación en la AVDCORR entre localidades (p= 0,0015) con gran variación dentro de localidades (DE promedio= 7,45 μg/g; n= 36). No se observó diferencia en la AVDCORR al agrupar los emplazamientos por paisaje (p= 0,1452)

Allogeneic bone marrow transplantation for Pearson's syndrome

n/

Gabapentin as add-on to morphine for severe neuropathic or mixed pain in children from age 3 months to 18 years - Evaluation of the safety, pharmacokinetics, and efficacy of a new gabapentin liquid formulation: Study protocol for a randomized controlled trial

Background: Gabapentin has shown efficacy in the treatment of chronic neuropathic or mixed pain in adults. Although pediatric pain specialists have extensive experience with gabapentin for the treatment of neuropathic pain, its use is off-label. Its efficacy and safety in this context have never been shown. The aim of this trial is to compare gabapentin with placebo as add-on to morphine for the treatment of severe chronic mixed or neuropathic pain in children. This trial is part of the European Union Seventh Framework Programme project Gabapentin in Paediatric Pain (GAPP) to develop a pediatric use marketing authorization for a new gabapentin suspension. Methods/design: The GAPP-2 study is a randomized, double-blind, placebo-controlled, multicenter superiority phase II study in children with severe chronic neuropathic or mixed pain. Its primary objective is to evaluate the efficacy of a gabapentin liquid formulation as adjunctive therapy to morphine. Sixty-six eligible children 3 months to 18 years of age with severe pain (pain scores ≥ 7), stratified in three age groups, will be randomized to receive gabapentin (to an accumulating dose of 45 to 63 mg/kg/day, dependent on age) or placebo, both in addition to morphine, for 12 weeks. Randomization will be preceded by a short washout period, and treatment will be initiated by a titration period of 3 weeks. After the treatment period, medication will be tapered during 4 weeks. The primary endpoint is the average pain scores in the two treatment groups (average of two measures each day for 3 days before the end-of-study visit [V10] assessed by age-appropriate pain scales (Face, Legs, Activity, Cry, Consolability scale; Faces Pain Scale-Revised; Numeric Rating Scale). Secondary outcomes include percentage responders to treatment (subjects with 30% reduction in pain scale), number of episodes of breakthrough pain, number of rescue interventions, number of pain-free days, participant dropouts, quality of life (Pediatric Quality of Life Inventory), and acceptability of treatment. Outcomes will be measured at the end-of-study visit after 12 weeks of treatment at the optimal gabapentin dose. Groups will be compared on an intention-to-treat basis. Discussion: We hope to provide evidence that the combination of morphine and gabapentin will provide better analgesia than morphine alone and will be safe. We also aim to obtain confirmation of the recommended pediatric dose. Trial registration: EudractCT, 2014-004897-40. Registered on 7 September 2017. ClinicalTrials.gov, NCT03275012. Registered on 7 September 2017

The research gap in chronic paediatric pain: A systematic review of randomised controlled trials

Background and Objective: Chronic pain is associated with significant functional and social impairment. The objective of this review was to assess the characteristics and quality of randomized controlled trials (RCTs) evaluating pain management interventions in children and adolescents with chronic pain. Methods: We performed a systematic search of PubMed, Embase and the Cochrane Library up to July 2017. We included RCTs that involved children and adolescents (3 months-18 years) and evaluated the use of pharmacological or non-pharmacological intervention(s) in the context of pain persisting or re-occurring for more than 3 months. Methodological quality was evaluated using the Cochrane Risk of Bias (ROB) Tool. Results: A total of 58 RCTs were identified and numbers steadily increased over time. The majority were conducted in single hospital institutions, with no information on study funding. Median sample size was 47.5 participants (Q1,Q3: 32, 70). Forty-five percent of RCTs included both adults and children and the median of the mean ages at inclusion was 12.9 years (Q1,Q3: 11, 15). Testing of non-pharmacological interventions was predominant and only 5 RCTs evaluated analgesics or co-analgesics. Abdominal pain, headache/migraine and musculoskeletal pain were the most common types of chronic pain among participants. Methodological quality was poor with 90% of RCTs presenting a high or unclear ROB. Conclusions: Evaluation of analgesics targeting chronic pain relief in children and adolescents through RCTs is marginal. Infants and children with long-lasting painful conditions are insufficiently represented in RCTs. We discuss possible research constraints and challenges as well as methodologies to circumvent them. Significance: There is a substantial research gap regarding analgesic interventions for children and adolescents with chronic pain. Most clinical trials in the field focus on the evaluation of non-pharmacological interventions and are of low methodological quality. There is also a specific lack of trials involving infants and children and adolescents with long-lasting diseases

Inseguridad y política: el miedo como operador estratégico en las campañas electorales en Argentina

In Argentina, insecurity has acquired political, mediatic and social relevance, and has been transformed in a recurring topic in political communication. The aim of this paper is to analyze, from a perspective that combines discourse theories approaches with the contributions of political philosophy, the regularities and dispersions present in television spots for election campaigns related to insecurity